Cell Genesys pact highlights cancer vaccine value

Cell Genesys' $320 million partnership deal with Takeda for its GVAX prostate cancer vaccine thrilled investors, who boosted the South San Francisco biotech's stock by 31 percent after the announcement. The Motley Fool sounds unimpressed by the numbers, but $50 million upfront is a solid standout in the development field. Takeda is also an experienced player in the prostate cancer field, with a successful track record for the hormone therapy Lupron. The cancer vaccine is in two late stage studies, with data due in 2009. In the meantime, analysts have also been pondering the possible implications the Cell Genesys deal could have on a pact covering Dendreon's immunotherapy, Provenge.

- read the report in the Motley Fool

ALSO: Cuba has begun clinical testing of an experimental prostate cancer vaccine. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.